Moleculin Biotech, Inc. 8-K Report: Key Updates as of February 11, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

Company Information:

Name: Moleculin Biotech, Inc.
State of Incorporation: Delaware (DE)
CIK Number: 0001659617
SEC File Number: 001-37758
Employer Identification Number (EIN): 47-4671997
Headquarters Address: 5300 Memorial Drive, Suite 950, Houston, TX 77007
Contact Number: 713-300-5160

Report Type:

Form: 8-K (Current Report)

Reporting Date:

Date of Filing: February 11, 2025
Period Covered: February 11, 2025 (indicating this report captures events occurring on that specific date)

Stock Information:

Type of Securities: Common Stock
Par Value: $0.001 per share
Ticker Symbol: MBRX
Exchange: NASDAQ

Document Information:

Schema Reference: The report references an XML schema file named "mbrx-20250211.xsd".

Insights:

This is a current report (8-K) indicating that Moleculin Biotech, Inc. is likely disclosing significant events or changes that occurred on February 11, 2025.
The inclusion of the stock information suggests that this may involve corporate actions that could affect shareholders, such as announcements related to financial performance, regulatory filings, or other critical events impacting the company's operations or stock price.
The report is filed with the SEC, adhering to regulatory requirements for timely disclosure of pertinent information to investors and stakeholders.

Overall, the report provides foundational data about the company and its securities, crucial for investors and analysts monitoring Moleculin Biotech's activities.